DENVER, CO / ACCESSWIRE / November 12, 2015 / Phoenix Pharms Capital Corporation, a private equity firm investing in the future of the legal medical cannabis industry is pleased to announce the launch of Phoenix Capital Partners Ltd and Boulder Ranch Partners LP, a $18,850,000 venture fund dedicated to the expansion of Phoenix's footprint in the emerging and rapidly expanding medical cannabis space.
Boulder Ranch Partners LP (the "Fund") is a limited partnership that will invest in real estate and infrastructure to provide access to licensed operators for organic farming of CBD dominant industrial hemp as well as pharmaceutical grade extraction and processing.
Phoenix Capital Partners Ltd has been established asis the general partner for investments into real estate and infrastructure to support the strategic initiatives of Phoenix Pharms Capital Corporation. Created in August 2015, Phoenix Capital Partners was formed in partnership with Vincent Coviello and Richard Maher to provide a real estate and infrastructure management group.
"The Fund was designed to provide investors with the security of the real estate coupled with direct participation benefits, and tax advantages similar to an investment in oil and gas," said Vincent Coviello, Phoenix's Chief Investment Officer.
Information regarding the investment in Boulder Ranch Partners can be obtained from the company by calling 888.733.6220 or emailing firstname.lastname@example.org to obtain a copy of the confidential private placement memorandum. The offering is solely available to accredited investors under Rule 506(c) of Regulation D promulgated by the SEC under the Securities Act.
The Fund intends to generate revenue through the leasing of the ranch to key operators in the medical and pharmaceutical cannabis industry. Through the relationships Phoenix Pharms has been able to create over past two years, we have assembled a group of professional and proven operators to lease these facilities and enter into joint venture partnerships with Phoenix Pharms.
The purpose of engaging with former fund manager and real estate professional Mr. Vincent Coviello and FDIC cleared bank founder, Mr. Richard Maher was to provide Phoenix Pharms with a foundation on which to create a series of limited partnership investment funds to purchase real estate across the United States and Internationally, invest in infrastructure and lease out facilities to key operators in the medical cannabis industry.
Martin Tindall, Director of Phoenix Pharms Capital Corporation said, "By providing an investment in real estate and infrastructure through a limited partnership and through direct placement, we can provide investors with the security and peace of mind of real estate, while maximizing returns through high yielding triple net leases."
About Phoenix Pharms Capital Corporation
Phoenix Pharms Capital Corporation is a provider of strategic investment and business incubation services for the medical cannabis industry. Our mission is to capitalize and finance the national rollout of commercial enterprises focused on the utilization of cannabinoid treatment protocols.
Our targeted partners are commercial growing operators, bio pharmaceutical companies, manufacturing and distribution centers, technology providers, and treatment and research organizations within the United States and Internationally.
Our investment portfolio and strategic partnerships include leading edge companies and industry experts who are dedicated to expanding the safe and legal access to products with where extracts from the cannabis plant are used as an active ingredient. We are seeking to align with partners whom are focused on the positive impact of cannabinoids for the management and potential treatment of specific health related conditions.
Phoenix Pharms Capital Corporation strives to provide maximum return to our stakeholders, including investors, partners, vendors, employees, and the community, through sustainable, scalable, profit and value driven enterprises and activities.
Phoenix Pharms Capital Corporation's current medical portfolio includes, MediJane Holdings (a publicly traded company CBD company (Stock Symbol: MJMDD), ClinicalwoRx a national privately held clinical sales organization, Phoenix Bio Pharmaceuticals, an intellectual property company specializing in medical delivery systems for compound products containing bioorganic active ingredients.
For more information, visit www.phoenixpharmscapital.com.
About MediJane Holdings Inc. (MJMD)
MediJane is in the business of marketing and distributing products within the legal medical cannabis industry, including transdermal patches, capsules, sublingual sprays, oral strips, and other medical products infused with cannabidiol (CBD). MediJane products give doctors, medical professionals and patient advocates the ability to provide patients accurate doses of cannabinoids to manage and treat pain and other specific illnesses.
For more information, visit www.medijane.co.
Disclaimer/Safe Harbor: Some information in this press release may constitutes forward-looking statements or statements which may be deemed or construed to be forward-looking statements. The words "plan," "forecast," "anticipates," "estimate," "project," "intend," "expect," "should," "believe," and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to, known and unknown risks, uncertainties and other factors which could cause actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in the individual companies' filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to any company herein are expressly qualified in their entirety by the above-mentioned cautionary statement. All companies included in this press release disclaim any obligation to update forward-looking statements contained in this press release, except as may be required by law.
FDA Disclosure: Any and all medically oriented statements and products have not been evaluated by the Food and Drug Administration.
SOURCE: Phoenix Capital Partners Ltd